Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- KM Biologics Teams Up with JB for Marketing of Globulin Product
January 28, 2020
- Otsuka’s Anti-CGRP Antibody Fremanezumab Smashes Primary Goals in Japan PII/III Studies for Migraine Prevention
January 28, 2020
- Xofluza Holds Top Spot in GP Promotion Ranking in December: Impact Track
January 27, 2020
- Opdivo Misses OS Goal in Platinum-Resistant Ovarian Cancer in PIII: Ono
January 27, 2020
- Amgen Astellas BioPharma to Become Amgen’s Wholly Owned Subsidiary; Continue Copromotion with Astellas
January 24, 2020
- Takeda to Liquidate Shire’s Irish Holding Firm
January 23, 2020
- Kissei’s Spinocerebellar Degeneration Drug Fails to Meet Primary Goal in PIII, but Shows Positive Results in Severe Patients
January 23, 2020
- Otsuka Ties Up with UK’s PhoreMost, Initial Focus on Gene Therapy
January 22, 2020
- Towa to Develop Adherence Support Tools with Game Maker, Eyes Launch in FY2021
January 22, 2020
- Pfizer Rolls Out Japan’s Second Rituxan Biosimilar
January 21, 2020
- GSK, NCC Join Hands to Propel Cancer Drug Development, Translational Research
January 21, 2020
- Keytruda Snags Best-Seller Title in 2019 Drug Ranking: Encise
January 20, 2020
- Xolair’s Use Would Be Limited to 1-3% of Pollen Allergy Patients in Japan: Specialist
January 20, 2020
- Forxiga Filed for Chronic Heart Failure in Japan: AstraZeneca
January 20, 2020
- Nichi-Iko Quits Herceptin Biosimilar, Focus Now on Avastin Follow-On
January 20, 2020
- Mitsubishi Tanabe to Be Delisted from TSE on February 27
January 20, 2020
- Astellas to Build New API Facility for Prograf in Toyama
January 20, 2020
- Astellas Completes US$3 Billion Audentes Buyout
January 17, 2020
- Asahi Kasei Closes Veloxis Acquisition
January 16, 2020
- JT Grabs Japan Rights to Dermavant’s Psoriasis/Eczema Drug
January 16, 2020
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…